Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Lymphomas, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, aggressive lymphoma, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Lymphomas, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, aggressive lymphoma, Lymphoid Malignancies
Sunday, December 12, 2021: 4:30 PM-6:00 PM
Thomas Murphy Ballroom 1-2, Level 5, Building B
(Georgia World Congress Center)
Moderators:
Mark Roschewski, MD, National Cancer Institute
and
Laurie H. Sehn, MD, British Columbia Cancer Agency
Disclosures:
Sehn: Novartis: Consultancy; Genmab: Consultancy; Debiopharm: Consultancy; Teva: Consultancy, Research Funding; Roche/Genentech: Consultancy, Research Funding; AbbVie: Consultancy; Acerta: Consultancy; Amgen: Consultancy; Apobiologix: Consultancy; AstraZeneca: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Incyte: Consultancy; Janssen: Consultancy; Kite: Consultancy; Karyopharm: Consultancy; Lundbeck: Consultancy; Merck: Consultancy; Morphosys: Consultancy; Sandoz: Consultancy; Seattle Genetics: Consultancy; Takeda: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH